If an investigational new drug that was part of a trial showed evidence that it proved efficacious as determined likely by the RECIST version 1.1 guidelines which is a common measurement standard for tumors and the trial ended or was terminated, the principal investigator of the trial can write an Individual Patient Investigational New Drug application and submit to the FDA for approval on compassionate need. This is what was done in my case when the trial was terminated and it was shown I had a complete response to the trial drug. The FDA acted on the application within 24 hours and I was allowed to continue receiving the drug under compassionate use. The manufacturer agreed to continue supplying the drug and I continue to be closely monitored 8.5 years after the trial was terminated.